1. Lagging M, Wejstål R, Norkrans G, et al; Swedish Consensus Group. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infect Dis (Lond). 2016;49(8):561-75.
2. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809-16.
3. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.
4. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.
5. SFS 1982:763. Hälso- och sjukvårdslag.
6. Folkhälsomyndigheten. Hepatit C [citerat 17 april 2017].
7. Grebely J, Mauss S, Brown A, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis. 2016;63(11):1405-11.
8. Dore GJ, Altice F, Litwin AH, et al; C-EDGE CO-STAR Study Group. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625-34.
9. Puoti M, Panzeri C, Rossotti R, et al. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. Dig Liver Dis. 2014;46(Suppl 5):S206-11.
10. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63(2):364-9.
11. Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65(1 Suppl):S33-45.
12. Jerkeman A, Norkrans G, Lidman C, et al. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities – completion rates and efficacy. Eur J Gastroenterol Hepatol. 2014;26(5):523-31.
13. Thompson AJ. Australian recommendations forthe management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016;204(7):268-72.
14. Schütz A, Moser S, Marchart K, et al. Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-threshold drug treatment facility – a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol. 2016;111(6):903-5.